References
- Chang HH, Wang T-Y, Lee IH, Lee S-Y, Chen KC, Huang S-Y, Yang YK, Lu RB, Chen PS. 2016. C-reactive protein: a differential biomarker for major depressive disorder and bipolar II disorder. World J Biol. Psychiatry. Epub ahead of print. doi:10.3109/15622975.2016.1155746.
- Courtet P, Jaussent I, Genty C, Dupuy AM, Guillaume S, Ducasse D, Olie E. 2015. Increased CRP levels may be a trait marker of suicidal attempt. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 25:1824–1831.
- Fond G, Boyer L, Gaman A, Laouamri H, Attiba D, Richard J-R, Delavest M, Houenou J, Le Corvoisier P, Charron D, et al. 2015. Treatment with anti-toxoplasmic activity (TATA) for toxoplasma positive patients with bipolar disorders or schizophrenia: a cross-sectional study. J Psychiatr Res. 63:58–64.
- Fond G, Godin O, Brunel L, Aouizerate B, Berna F, Bulzacka E, Capdevielle D, Chereau I, Dorey JM, Dubertret C, et al. 2016. Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ data set. J Affect Disord. 191:209–215.
- Fond G, Macgregor A, Tamouza R, Hamdani N, Meary A, Leboyer M, Dubremetz JF. 2013. Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate. Eur Arch Psychiatry. Clin. Neurosci. 264:179–183.
- Lee S-Y, Chen S-L, Chang Y-H, Chen PS, Huang S-Y, Tzeng N-S, Wang Y-S, Wang L-J, Lee IH, Wang T-Y, et al. 2013. Inflammation's association with metabolic profiles before and after a twelve-week clinical trial in drug-naïve patients with bipolar II disorder. PLoS One. 8:e66847.
- Sutterland AL, Fond G, Kuin A, Koeter MWJ, Lutter R, van Gool T, Yolken R, Szoke A, Leboyer M, deHaan L. 2015. Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. Acta Psychiatr Scand. 132:161–179.